In contrast to ever-increasing expenses, the Restore Value Slate's plan would return the Company to a headcount and overhead expense level similar to the levels when Ms. Sooch was CEO. 2) Extending the Company's Cash Runway – Preserve cash by streamlining spend and maintaining a sustainable financial strategy that does not require any dilutive financings in the foreseeable future. In contrast to the current management, the Restore Value Slate's plan does not envision further dilution from additional equity raises. 3) Maximizing RYZUMVI™ Globally – Working closely with Viatris, leverage the valuable FDA-approved asset with zero capital requirements, near-term milestones and revenues, extensive patient data, upcoming potential large indication approvals, and significant commercial upside all around the world.